Vaxart, INC 8-K filings

Vaxart, Inc. announced a reorganization of its Board of Directors' Nominating and Governance and Compensation Committees, with new chairs appointed effective August 1, 2026.

Vaxart stockholders approved director elections and auditor ratification but rejected executive compensation in an advisory vote at the company's annual meeting.

Vaxart announced topline 12-month safety data from its Phase 2b trial, showing no vaccine-related serious adverse events in its oral COVID-19 vaccine candidate compared to an mRNA comparator.

Vaxart, Inc. has entered into a cooperation agreement with a stockholder group to resolve a proxy contest, leading to board and corporate governance enhancements.

Vaxart has modified its BARDA contract to reflect a reduced trial scope, securing $345 million in total funding to advance data analysis for its oral COVID-19 vaccine.

Vaxart, Inc. has filed preliminary proxy materials and issued a letter to shareholders urging support for its director nominees in an upcoming election, while also addressing a dissident shareholder's nominations.

Vaxart announces first quarter 2026 financial results, with $61.0 million in cash and anticipation of key COVID-19 trial data in Q2 2026.

Vaxart, Inc. has appointed Dr. James Breitmeyer to its Board of Directors to bolster its clinical and regulatory expertise.

Vaxart, Inc. has amended its lease agreement to expand its leased space in South San Francisco, California, effective May 14, 2026.

Vaxart has established a flexible $25 million share purchase agreement with Lincoln Park Capital to fund its oral vaccine pipeline and general operations.

Vaxart announced a significant financial turnaround in 2025 with net income and extended cash runway, alongside key advancements in its COVID-19 and norovirus vaccine programs.

Vaxart, Inc. has terminated its headquarters lease early, effective May 15, 2026, as part of a cost reduction strategy, with plans to relocate to another South San Francisco office.

Vaxart announced a significant licensing agreement with Dynavax for its COVID-19 oral vaccine candidate, potentially worth up to $700 million plus royalties, alongside reporting its third-quarter 2025 financial results and extending its cash runway into Q2 2027.

Vaxart and Dynavax Technologies Corporation have entered an exclusive worldwide license and collaboration agreement for Vaxart's investigational oral COVID-19 vaccine candidate.

Vaxart announced BARDA's decision to definitively exclude certain work from its Project Agreement, while funding continues for ongoing Phase 2b COVID-19 trial participant follow-up.

Vaxart, Inc. announced its common stock will be delisted from Nasdaq after failing to meet listing conditions, including the withdrawal of a reverse stock split proposal.

Vaxart, Inc. announced the withdrawal of a previously disclosed proposal from stockholder consideration, canceling its reconvened special meeting.

Vaxart, Inc. has adjourned its special meeting of stockholders to September 19, 2025, citing recent board changes and ongoing governance considerations.

Vaxart, Inc. announced that its Chairman, Michael J. Finney, Ph.D., will retire from the Board of Directors effective September 30, 2025.

Vaxart, Inc. received an extension from Nasdaq to regain compliance with the minimum bid price requirement, contingent on a reverse stock split and shareholder approval.

Vaxart's management strongly advocates for a reverse stock split to regain NASDAQ compliance, citing benefits for capital access, investor visibility, and corporate governance.

Vaxart, Inc. announced a virtual fireside chat for August 20, 2025, to discuss a reverse stock split proposal aimed at regaining Nasdaq compliance, supported by ISS and Glass Lewis.

Vaxart announced its second quarter 2025 financial results, highlighted by positive norovirus vaccine data and a stop work order for its COVID-19 Phase 2b trial.

Vaxart, Inc. received a stop work order from Advanced Technology International, halting most efforts on its BARDA-funded oral COVID-19 vaccine trial.

Vaxart, Inc. announced its common stock was delisted from The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement and has commenced trading on the OTCQX Best Market while the company appeals Nasdaq's decision.

Vaxart, Inc. has received a delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement, leading to a trading suspension effective July 8, 2025, with plans to move to the over-the-counter market.

Vaxart, Inc. announced the preliminary results of its reconvened 2025 Annual Meeting of Stockholders, revealing that while directors were elected and auditors ratified, shareholders rejected key proposals for a reverse stock split and executive compensation.

Vaxart, Inc. announced positive topline Phase 1 clinical trial results for its second-generation oral pill norovirus vaccine, demonstrating significantly stronger antibody responses and a favorable safety profile.

Vaxart, Inc. has adjourned its 2025 annual meeting of stockholders to June 13, 2025, to allow additional time for shareholders to vote on a critical proposal to enable a reverse stock split, deemed necessary for continued Nasdaq listing.

Vaxart, Inc. is urging stockholders to vote for a reverse stock split proposal by June 1, 2025, to regain Nasdaq compliance and addresses key investor concerns regarding financing, pipeline progress, and market dynamics.